If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
=== Harness with buoyancy compensation === The AP Valves Mk4 Jump Jacket is a harness with integral buoyancy jacket specifically designed for commercial diving work with helmets and bells. There is a direct feed to the jacket from the main air supply, via the helmet side-manifold block, from the pneumo line and from bailout, and a system which allows the diver's pneumo to be directly connected to another diver's helmet as an emergency air supply. The harness supports a single or twin cylinder bailout set, allows buoyancy control from slightly negative through neutral, to sightly positive, and has a safety harness for retaining the helmet.The Jump Jacket also serves as a recovery harness for rescues to the bell, and has front and back lifting points.
== Detection in body fluids == Levamisole may be quantified in blood, plasma, or urine as a diagnostic tool in clinical poisoning situations or to aid in the medicolegal investigation of suspicious deaths involving adulterated street drugs. About 3% of an oral dose is eliminated unchanged in the 24-hour urine of humans. A post mortem blood levamisole concentration of 2.2 mg/L was present in a woman who died of a cocaine overdose.
== Bodybuilding titles == 1984 Mr Birmingham Novice, 1st 1985 World Games, 7th Heavyweights 1986 British Championships, 1st Heavyweight 1988 British Championships, 1st Heavyweight and overall 1990 Night of Champions, 2nd 1991 Night of Champions, 1st 1991 Mr. Olympia, 2nd 1991 English Grand Prix, 1st 1992 Mr. Olympia, 1st 1992 English Grand Prix, 1st 1993 Mr. Olympia, 1st 1994 Mr. Olympia, 1st 1994 Mr. Worldwide, 1st 1994 Spanish Grand Prix, 1st 1994 German Grand Prix, 1st 1994 English Grand Prix, 1st 1995 Mr. Olympia, 1st 1996 Mr. Olympia, 1st 1996 Spanish Grand Prix, 1st 1996 German Grand Prix, 1st 1996 English Grand Prix, 1st 1997 Mr. Olympia, 1st
Psylocke is the alias of two connected characters appearing in American comic books published by Marvel Comics, commonly in association with the X-Men. Both characters are depicted as mutants, a subspecies of humans born with an "X-gene" that grants superhuman abilities. In the primary continuity of the Marvel Universe, the first and best-known incarnation of Psylocke is Betsy Braddock (created by Chris Claremont and Herb Trimpe), a British telepath who was introduced as a supporting character for her twin brother Brian in 1976. Betsy adopts the codename "Psylocke" upon joining the X-Men in 1986, and three years later takes on the appearance of a Japanese woman and the abilities of a ninja in a story written by Claremont and illustrated by Jim Lee. This redesign was retroactively revealed in 1993 as the result of a body swap with the ninja assassin Kwannon (created by Fabian Nicieza and Andy Kubert). Following 29 years of publication history, both women were returned to their respective bodies, and Betsy assumed the mantle of Captain Britain from her brother while Kwannon became the second Psylocke. The Ultimate Universe features two versions of Psylocke: Sai and Kanon Sainouchi (both created by Peach Momoko). In addition to their presence in numerous X-related team titles over the decades, both iterations of Psylocke have been featured in various limited series and one-shots. In 1997, Betsy Braddock, as Psylocke, appeared in the 4-issue team-up series Psylocke and Archangel: Crimson Dawn.
== Reproductive effects == Exposure to nitrogen dioxide has a significant effect on the male reproductive system by inhibiting the production of Sertoli cells, the "nurse" cells of the testicles that are part of a seminiferous tubule and help in the process of spermatogenesis. These effects consequently retard the production of sperm cells. The effects of nitrogen dioxide poisoning on female reproduction may be linked with the effects of oxidative stress on female reproduction. Nitrogen dioxide poisoning disrupts the balance of reactive oxygen species (ROS), which results in oxidative stress, leading to significant effects on the female reproductive lifespan. ROS play a significant role in body physiology, from oocyte production, development and maturation to fertilization, development of the embryo and gestation. Exposure to nitrogen dioxide causes ovulation-induced oxidative damage to the DNA of ovarian epithelium. There is a growing body of literature on the pathological effects of ROS on female reproduction as evidenced by free-radical-induced birth defects, abortions, hydatidiform moles and pre-eclampsia. ROS also play a significant role in the etiopathogenesis of endometriosis, a disease in which tissue that normally grows inside the uterus grows outside of it. Oxidative stress causes defective placentation, which is likely to lead to placental hypoxia, shortage of oxygen in the placental as well as reperfusion injury resulting from ischemia, which may lead to endothelial cell dysfunction.
Sources: en.wikipedia.org
=== Behavioral evidence === Fossils of the troodonts Mei and Sinornithoides demonstrate that some dinosaurs slept with their heads tucked under their arms. This behavior, which may have helped to keep the head warm, is also characteristic of modern birds. Several deinonychosaur and oviraptorosaur specimens have also been found preserved on top of their nests, likely brooding in a bird-like manner. The ratio between egg volume and body mass of adults among these dinosaurs suggest that the eggs were primarily brooded by the male and that the young were highly precocial, similar to many modern ground-dwelling birds. Some dinosaurs are known to have used gizzard stones like modern birds. These stones are swallowed by animals to aid digestion and break down food and hard fibers once they enter the stomach. When found in association with fossils, gizzard stones are called gastroliths.
"The most important and primary role of the African Renaissance Institute now and in the coming years is to gather a critical mass of first-class African scientists and to give them large enough grants on a continuing basis, as well as sufficient infrastructure, to enable them to undertake meaningful problem-solving R&D applied to industrial production that will lead to really important results of economic dimensions."
proteinase Also endopeptidase or endoproteinase. Any enzyme that catalyzes the hydrolysis of peptide bonds more readily in intact, properly folded proteins than in small peptide molecules. Proteinases may be considered a subclass of proteases, though the terms are also often used interchangeably.
== Signs and symptoms == Physical symptoms of CMRD involving the development and function of the gastrointestinal tract and nervous system typically manifest between infancy and adolescence. The symptoms of CmRD are similar to the physical symptoms of malnutrition, as the disease arises due to the poor absorption of lipids and fat-soluble nutrients such as vitamin E. For this reason, the disease is likely to be underdiagnosed by physicians. Fat-soluble nutrients are essential for growth, development, and normal bodily function. Vitamin E deficiency is especially serious, as the vitamin is necessary for proper neurological function and development. Without Vitamin E, neurons cannot operate correctly and signals from the brain are weakened. This leads to reduced muscle development and reduced muscle contraction. Symptoms that manifest in the GI tract are likely to be a consequence of both reduced absorption of fats and physiological stress imposed on enterocytes that can not shuttle fats into circulation. Additional symptoms that occur throughout the body can be attributed to the lack of sufficient lipid sources.
Sources: en.wikipedia.org
Thorburn Brailsford Robertson (4 March 1884 – 18 January 1930), generally known as Brailsford Robertson, was an Australian academic, physiologist, biochemist, gerontologist, and animal nutritionist. Driven by his view, "Do the best you can with what you have where you are", he was "widely regarded as having possessed a rare capacity both as a teacher and researcher". Robertson's assignment of the rights to his tethelin patent (BR.18, BR.19) to the University of California (UC.6) in September 1917 is universally treated as a landmark precedent event in the subsequent development of what is now known as university technology transfer. His initial research interests were in the physical and biochemical processes underlying nervous activity, cognition, human growth, and senescence. Following the Canadian discovery of insulin, he became deeply involved in both researching the insulin treatment of diabetes mellitus and the Australian production of insulin, which he undertook (in mid-1922) with the direct permission (and precise details of its production) of the Head of the Physiology Department of the University of Toronto, John Macleod, Robertson's former assistant at Toronto, centred on the campus of the University of Adelaide: not only refining and purifying its extraction from bovine pancreases, but also significantly reducing its cost per dose, prior to its full-scale commercial production being transferred to the Commonwealth Serum Laboratories on 1 May 1924.
=== Leader of the BC Conservatives (May–September 2026) === On May 30, 2026, Findlay was elected leader of the Conservative Party of British Columbia with 51% of the vote. She took over from interim leader Trevor Halford following the resignation of John Rustad in December 2025. During the leadership campaign, Findlay faced criticism within her own party for saying fellow leadership candidate Peter Milobar had a conflict of interest when it comes to reconciliation because his wife is Indigenous. In response, Milobar called Findlay's attacks "the worst side of politics possible,” suggesting her victory would “give a lot of British Columbians pause for thought of whether they would actually vote for a party like this.” He would later leave the party in August 2026. Findlay has also received criticism from former Conservative MLA Elenore Sturko, who called her "radical on the right wing," saying she’s been copied on several emails from B.C. Conservative members cancelling their memberships. Former BC United MLA Karin Kirkpatrick called Findlay's victory "very, very bad for the Conservative party." On June 29, she conducted a shadow cabinet reshuffle, appointing MLA Heather Maahs as leader of the Opposition. On July 3, 2026, former BC Conservative MLA Amelia Boultbee crossed the floor to join the governing BC NDP caucus, citing a shift toward "Trump-style populism" under new BC Conservative leader Findlay as the reason she would not be returning to its caucus.
== Mechanism of action == D-Ribose-L-cysteine functions as a cysteine prodrug, delivering cysteine in a chemically protected form that may resist premature oxidation. After cellular uptake, enzymatic cleavage releases free L-cysteine, which can then enter the γ-glutamyl cycle for glutathione synthesis. This mechanism differs from N-acetylcysteine, which relies on de-acetylation and exhibits different absorption and metabolic characteristics. While both compounds ultimately increase cysteine availability, direct comparative data in humans remain limited.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.